Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group

Table 2 Previous treatments and trabectedin administration

Pt no.	Prior systemic treat. before trab.	Best RECIST response to systemic treatments	Reason for discontinuing therapy	Disease status just before starting trab.	Numb of trab. cycles	Dose decr.	Reason for stopping trab.
1^a	A →	SD →	Stab.	PD (L + M)	10	Y	Stab.
	Soraf n°1 →	SD →	Stab.
	Soraf. n°2 →	SD →	Stab.
	Soraf. n°3 →	SD →	Progr.
2	Soraf	PD	Progr.	PD (M)	9	N	Stab.
3	AI	PD	Progr.	PD (L + M)	6	N	Progr.
4	A	PR	Stab.	PD (L + M)	12	Y	Tox.
5	AI	SD	Stab.	PD (M)	11	N	Stab.
6	Ima →	SD →	Prog.	PD (L + M)	12	N	Stab.
	AD →	SD →	Stab.
	Cy →	SD →	Progr.
	Soraf. →	PD →	Tox.
7	A →	SD →	Stab.	PD (L + M)	2	N	Progr.
	Cy →	PD →	Progr.
	Suni →	SD →	Progr.
	Bev + Tmz →	SD →	Progr.
8	MAID	SD	Stab.	PD (M)	4	N	Tox.
9	AI	SD	Progr.	PD (M)	3	N	Progr.
10	AD	SD	Stab.	PD (L + M)	6	N	Stab.
11	PLK-Inh.	PD	Progr.	PD (L + M)	11	N	Progr.

L local, M metastatic, trab. trabectedin, dose decr. dose decrease, A adriamycin, I ifosfamide, D dacarbazine, M Mesna, Cy cyclophosphamide, Soraf sorafenib, Ima imatinib, Suni sunitinib, Bev + Tmz bevacizumab + temozolomide, PLK-Inh Polo-Like Kinase inhibitor, SD stable disease, PD progressive disease, Y yes, N no, Stab disease stabilization, Progr disease progression, Tox toxicity
^aPatient 1 received sorafenib three times, in three successive lines of treatment

ISSN: 1471-2407